Forecast
Medical intervention extends typical healthy human lifespan by multiple decades by 2126.
Last revised Sep 10, 2026.
Current estimate
probability this has happened by each date
Healthy life expectancy in at least one of the longest-lived populations exceeds its 2026 value by at least twenty years, shown by replicated population evidence and attributable to medical intervention.
Resolution criteria
- 2126
- Healthy life expectancy in at least one of the longest-lived populations exceeds its 2026 value by at least twenty years, shown by replicated population evidence and attributable to medical intervention.
Probability history
| Revised | State | p(2035) | p(2050) | p(2100) |
|---|---|---|---|---|
hf-forecast-0017 | researched | — | — | — |
hf-forecast-0008 | initial prior | — | — | — |
Strongest evidence for
- Rapamycin raised median mouse lifespan 23 to 26 percent across three independent sites; the same proportional effect on an eighty-year human life would be about eighteen years, so the mechanism class is not numerically absurd (hf-evidence-0007).
- Partial reprogramming acts on already-old animals rather than delaying onset, which is a qualitatively different lever from disease-by-disease medicine (hf-evidence-0010).
- Senolytics show the mechanism is druggable in humans, not only in animals (hf-evidence-0009).
- A modelled 1.9-year gain from semaglutide in a high-risk population shows a broad intervention can plausibly move population life expectancy at all (hf-evidence-0012).
- The horizon is a full century and the forecast needs only one success within it, so the current absence of translation is evidence about now rather than about 2126.
Strongest evidence against
- Frontier life expectancy improvement has decelerated below 0.2 years per year, and the authors of that analysis put the optimistic ceiling at 15 percent of females and 5 percent of males reaching 100 this century (hf-evidence-0013).
- The healthspan-lifespan gap widened from 8.5 to 9.6 years between 2000 and 2019, so added years are increasingly unhealthy ones (hf-evidence-0014).
- Global healthy life expectancy gained about 2.8 years per decade to 2019, largely through poorer countries converging on the frontier, and then gave back 1.6 years by 2021 (hf-evidence-0015).
- The slowdown appears simultaneously in all seventeen European countries studied, so it is structural rather than local (hf-evidence-0016).
- The flagship human trial of an ageing indication has not launched or enrolled and is still seeking funding, so the human evidence pipeline is stalled rather than merely immature (hf-evidence-0008).
- The best measured survival gain from a mass-deployed medicine is 12.6 days for statins, and the paper's authors warn explicitly against extrapolating it to years (hf-evidence-0011).
- Translation, not mechanism discovery, is the acknowledged bottleneck, and no trial yet uses ageing as an endpoint (hf-evidence-0017).
Present uncertainties
- The dominant uncertainty is no longer whether the biology is real but whether human translation, regulatory recognition of ageing as an indication, and population-scale attribution can all occur inside a century.
Next discriminating observation
A first adequately powered human trial that uses an ageing or composite healthspan endpoint reaching enrolment, and the first year in which healthy life expectancy at the frontier resumes rising faster than life expectancy.
Sources
- Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
In genetically heterogeneous mice across three NIA Interventions Testing Program sites, dietary rapamycin at 42 ppm begun at nine months raised median lifespan by 23 percent in males and 26 percent in females.
Limit: One species and stock, median lifespan rather than healthspan, and the effect was dose and sex dependent, with lower doses producing smaller or absent effects in males.
recorded
- TAME — Targeting Aging with Metformin, trial sponsor status page
The sponsor's own page shows TAME has not launched and has not enrolled: it still seeks visionary donors to launch the multi-site trial and the 3,000 participants aged 65 to 79 it requires, with an aging indication described as a future goal.
Limit: A stalled trial does not show the intervention would fail; it shows the human evidence does not yet exist and that funding, not biology, is the binding constraint so far.
Fetched and confirmed directly by the master agent, not accepted from a delegated summary.
- Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease
Nine subjects given a single three-day course of dasatinib plus quercetin showed reduced adipose senescent-cell markers, including a 35 percent fall in p16INK4A-positive cells and an 86 percent fall in crown-like structures at day 14, with lower circulating SASP factors.
Limit: Nine subjects, open label with no placebo control, three days of treatment and fourteen days of observation, and no clinical endpoint of any kind was measured.
recorded
- Gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice
In male mice first treated at 124 weeks of age, inducible AAV-delivered OSK extended median remaining lifespan by 109 percent, from 8.86 to 18.5 weeks, moving median total lifespan from 133 to 142.5 weeks and lowering a frailty index from 7.5 to 6.0.
Limit: Male mice only, no scramble or GFP control arm which the authors themselves flag, near-end-of-life animals only, and a single laboratory and species.
recorded
- Postponement of death by statin use: a systematic review and meta-analysis of randomized clinical trials
Across sixteen randomized trials of roughly three to six years, statin use postponed death by a median of 12.6 days overall, 10.2 days in primary prevention and 17.4 days in secondary prevention, measured within trial duration; the authors note published lifetime projections range from three months to 7.9 years and rest on untestable assumptions and unrealistic lifelong adherence.
Limit: Within-trial postponement understates lifetime benefit, and a modest average gain can still coexist with large gains in a small high-risk subgroup.
Fetched and confirmed directly by the master agent, not accepted from a delegated summary.
- Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK
Applying SELECT trial hazard ratios to a UK population with cardiovascular disease and overweight or obesity projects a life-expectancy gain of 1.9 years, 95 percent confidence interval 1.27 to 2.70, largest at ages 45 to 49 at 2.3 years and 1.7 years at ages 70 and above.
Limit: Modeled rather than measured, in a high-risk subpopulation rather than the general population, over trial follow-up of about three to four years with 26.7 percent in-trial discontinuation, and assuming constant lifelong effect and full adherence.
recorded
- Implausibility of radical life extension in humans in the twenty-first century
Across the nine longest-lived populations from 1990 to 2019 the annual rise in life expectancy at birth decelerated to below 0.2 years per year in every population except Hong Kong and South Korea, the observed probability of current birth cohorts reaching age 100 is 5.1 percent for females and 1.8 percent for males, no population comes close to 50 percent survival to 100, and the authors state it would be optimistic if 15 percent of females and 5 percent of males in any birth cohort reached 100 this century.
Limit: The conclusion is explicitly conditioned on biological ageing not being markedly slowed; it is a demographic extrapolation, not a proof that a geroscience breakthrough is impossible.
Fetched and confirmed directly by the master agent.
- Global healthspan-lifespan gaps among 183 World Health Organization member states
Across 183 member states the healthspan-lifespan gap widened from 8.5 years in 2000 to 9.6 years in 2019, a 13 percent rise, with a mean gap of 9.2 years, a gap 2.4 years wider for women than men, and the largest national gap in the United States at 12.4 years.
Limit: A trend through 2019 documents failure to compress morbidity so far; it does not establish a ceiling on future intervention, and an intervention that targets ageing itself could in principle narrow the gap rather than widen it.
Fetched and confirmed directly by the master agent.
- WHO Global Health Observatory, life expectancy and healthy life expectancy
Global life expectancy rose from 66.8 years in 2000 to 73.1 in 2019 while healthy life expectancy rose from 58.1 to 63.5, and both fell afterwards to 71.4 and 61.9 by 2021, with the pandemic reversing roughly a decade of gains.
Limit: Global gains over this period are driven substantially by lower-income countries converging on the frontier rather than by the frontier advancing, so the global rate overstates what is available to already long-lived populations; the post-2019 decline is pandemic-driven and may partially recover.
Fetched and confirmed directly by the master agent.
- Slowdown in life expectancy improvements for European countries from 2000 to 2019
All seventeen European countries studied experienced a slowdown in life expectancy improvement after 2010 compared with the 2000 to 2010 decade, with the deceleration ranging from about 0.75 years in Denmark to about 2.77 years in Ireland.
Limit: It reports the change in the rate of improvement between two decades rather than the absolute pace remaining, and the window ends before the pandemic.
Retrieved by a delegated source worker and not independently re-fetched by the master agent.
- A grand challenge in aging interventions: from mice to humans
The review states that despite many interventions that extend lifespan in rodents, nematodes, yeast and flies, it remains unknown whether most will work in humans, that rapamycin's mouse result was never carried forward into human translation, and that only disease-specific trials are under way rather than trials with ageing as an endpoint.
Limit: It documents a bottleneck as of writing rather than proving translation impossible, and no source located in this cycle quantifies the mouse-to-human failure rate, which remains unverified.
Retrieved by a delegated source worker and not independently re-fetched by the master agent.